Genetic manipulation of myocardial beta-adrenergic receptor activation and desensitization

Journal of Molecular and Cellular Cardiology
Jonathan A HataWalter J Koch

Abstract

Heart failure (HF) represents one of the leading causes of morbidity and mortality in developed nations today. Although this disease process represents a final common endpoint for several entities, including hypertension, coronary artery disease, and cardiomyopathy, a predominant characteristic of end-stage HF is an altered beta-adrenergic receptor signaling cascade. In the heart, beta-adrenergic receptors (beta ARs), members of the superfamily of G-protein-coupled receptors (GPCRs), modulate cardiac function by controlling chronotropic, inotropic, and lusitropic responses to catecholamines of the sympathetic nervous system. In HF, beta ARs are desensitized and downregulated in a maladaptive response to chronic stimulation. This process is largely mediated by G-protein-coupled receptor kinases (GRKs), which phosphorylate GPCRs leading to functional uncoupling. The most abundant cardiac GRK, known as GRK2 or beta AR kinase 1 (beta ARK1), is increased in human HF, and has been implicated in the pathogenesis of dysfunctional cardiac beta AR signaling. The association of beta ARs and GRKs with impaired cardiac function has been extensively studied using transgenic mouse models, which have demonstrated that beta ARK1 plays a vital r...Continue Reading

Citations

Feb 11, 2014·Pflügers Archiv : European journal of physiology·Kristina LorenzFriederike Cuello
Apr 11, 2006·American Journal of Physiology. Heart and Circulatory Physiology·Nicole D GlaserTerry B Rogers
Jul 4, 2007·The Journal of Clinical Investigation·Sandrine BilletEric Clauser
Jun 21, 2008·Circulation Research·Leif Erik VingeWalter J Koch
Jun 26, 2008·Molecular Therapy : the Journal of the American Society of Gene Therapy·Ekaterina V FomichevaJoseph M Metzger
Oct 1, 2011·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Einat KodeshMichal Horowitz
Jan 12, 2013·Current Cardiology Reports·Charbel NaimRoger J Hajjar
Nov 3, 2005·Nature Clinical Practice. Cardiovascular Medicine·David S FeldmanMichael R Bristow
Feb 20, 2007·Annual Review of Physiology·Richard T Premont, Raul R Gainetdinov
Feb 27, 2007·Nature Medicine·Anastasios LymperopoulosWalter J Koch
Oct 15, 2009·Annual Review of Medicine·C Thomas Caskey
Mar 21, 2008·Fundamental & Clinical Pharmacology·Otto-Erich Brodde
Mar 14, 2009·Journal of Zhejiang University. Science. B·He LiGuo-yuan Zhang
Mar 15, 2005·The Journal of Clinical Investigation·Gerald W Dorn, Thomas Force
Apr 14, 2006·Journal of Pharmacological Sciences·Otto-Erich BroddeKirsten Leineweber
Sep 20, 2005·Molecular Therapy : the Journal of the American Society of Gene Therapy·Sven T PlegerPatrick Most
Dec 4, 2014·Lancet·Eugene Braunwald
Apr 6, 2017·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·SoHyun LeeBenjamin Bonavida
Sep 12, 2018·Diabetes, Obesity & Metabolism·Rebecca K C LohAndrew L Carey
Aug 22, 2013·Journal of the American Heart Association·Julie A Wolfram, J Kevin Donahue
Jul 23, 2011·Circulation Research·Stephen L Belmonte, Burns C Blaxall
Mar 3, 2012·Circulation Research·Lisa TilemannRoger J Hajjar
Jul 25, 2007·Circulation·Houman AshrafianLionel H Opie
Feb 23, 2005·Expert Review of Cardiovascular Therapy·Fariya BukhariRoger J Hajjar
May 7, 2010·Clinical and Translational Science·Raphael E BonitaWalter J Koch
May 24, 2006·Expert Review of Cardiovascular Therapy·Douglas G Tilley, Howard A Rockman
Oct 17, 2008·Physiological Reviews·Jennifer DavisJoseph M Metzger
Jan 3, 2013·The Journal of Clinical Investigation·Roger J Hajjar
Aug 8, 2013·Journal of Cardiovascular Pharmacology·Armen YerevanianRoger J Hajjar
Aug 16, 2013·Expert Review of Cardiovascular Therapy·Shripad N Pal, Theodoros Kofidis
Aug 12, 2014·The Journal of Biological Chemistry·Melanie PhilippMarc G Caron
Mar 27, 2015·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Jeremy SandgrenJeffrey L Segar
Dec 13, 2018·Frontiers in Pharmacology·Supachoke MangmoolHitoshi Kurose
Jul 2, 2014·ACS Chemical Biology·Kristoff T Homan, John J G Tesmer
Nov 16, 2010·Archives of Cardiovascular Diseases·Mario T Njeim, Roger J Hajjar
Mar 5, 2011·Journal of the American College of Cardiology·Yoshiaki KawaseRoger J Hajjar

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.

Cardiomegaly

Cardiomegaly, known as an enlarged heart, is a multifactorial disease with different pathophysiological mechanisms. Hypertension, pregnancy, exercise-induced and idiopathic causes are some mechanisms of cardiomegaly. Discover the latest research of cardiomegaly here.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Related Papers

Journal of Molecular and Cellular Cardiology
Jason A Petrofski, Walter J Koch
Proceedings of the Association of American Physicians
Guido IaccarinoWalter J Koch
© 2022 Meta ULC. All rights reserved